Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone

Trial Identifier:	D6402C00013
Sponsor:	AstraZeneca
NCTID::	NCT06388616
Start Date:	May 2024
Primary Completion Date:	September 2024
Study Completion Date:	September 2024
Condition:	Liver, Pancreas & Gallbladder - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
US, FL	Hialeah, FL, US, 33014
US, FL	Orlando, FL, US, 32809
US, TX	San Antonio, TX, US, 78215

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.